Chronic Cutaneous Lupus Erythematosus Clinical Trial

What Is Chronic Cutaneous Lupus Erythematosus?

Chronic cutaneous lupus erythematosus (CCLE) is a long-lasting autoimmune condition that mainly affects the skin. It occurs when the immune system mistakenly attacks healthy skin cells, leading to chronic inflammation. CCLE most often appears as thick, scaly, red or purple patches on areas exposed to the sun, such as the face, scalp, and ears. Over time, these lesions can cause skin discoloration, scarring, and permanent hair loss on the scalp. Unlike systemic lupus erythematosus (SLE), CCLE is usually limited to the skin and does not commonly affect internal organs. While CCLE is chronic and can flare over time, early diagnosis and appropriate treatment can help control symptoms, reduce skin damage, and improve quality of life.

Cutaneous lupus clinical trials are exploring potential new treatments to improve the management of chronic cutaneous lupus erythematosus.

THARROS

Investigating a Potential New Treatment Approach for Cutaneous Lupus

This clinical trial is designed to evaluate a study drug in people with cutaneous lupus erythematosus. The main goal of the study is to assess how well the study drug works, how safe it is, and how well participants tolerate it over time. Researchers will closely monitor changes in skin symptoms, overall health, and any side effects throughout the study period. By carefully collecting this information, the trial aims to determine whether the study drug can help reduce disease activity and improve symptom control.

Participation in this skin lupus clinical trial may give patients access to an investigational treatment and close medical monitoring. It also helps advance research that could lead to better treatment options for others living with cutaneous lupus erythematosus.

Age
40-80 Years

Location:
Arizona and Colorado

Status:
Recruiting

Condition
Chronic Cutaneous Lupus Erythematosus

What to Expect in a Chronic Cutaneous Lupus Clinical Trial

In a chronic cutaneous lupus clinical trial, participants can expect a well-designed and closely monitored research process. After screening to confirm eligibility, participants may receive an investigational treatment depending on the trial design. Throughout the study, regular clinic visits are scheduled for skin exams, lab tests, and overall health assessments. Participants will report any changes in symptoms and describe how they feel and respond to the study treatment during the trial.

An experienced team of researchers closely monitors participants and ensures their safety throughout the trial. By joining this trial, participants can help researchers evaluate an investigational treatment for cutaneous lupus and improve future care options for people living with CCLE.

Frequently Asked
Questions

  • Adults aged 18 years and older who have been diagnosed with cutaneous lupus erythematosus may be eligible. Participants must meet specific health criteria determined during the screening process.

  • Participants will attend regular clinic visits for skin exams, lab tests, and overall health assessments. They may receive the study drug and will be closely monitored for changes in skin symptoms, any side effects, and overall well-being.

  • Participants may gain access to an investigational treatment and receive expert medical care. By joining, they can play an active role in developing improved cutaneous lupus treatment options.